Phase I/II Trial of the A-dmDT390-bisFv (UCHT1)Fusion Protein in Combination With Ionizing Radiation for the Treatment of Stage IV Melanoma

Trial Profile

Phase I/II Trial of the A-dmDT390-bisFv (UCHT1)Fusion Protein in Combination With Ionizing Radiation for the Treatment of Stage IV Melanoma

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 25 Nov 2016

At a glance

  • Drugs A-dmDT390-anti-CD3bisFv immunotoxin (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Sponsors Angimmune
  • Most Recent Events

    • 22 Nov 2016 Status changed from recruiting to discontinued as protocol replaced with combination therapy adding KEYTRUDA (pembrolizumab)
    • 24 Feb 2014 According to the ClinicalTrials.com, status changed from not yet recruiting to recruiting.
    • 18 Dec 2013 Planned initiation date (Jan 2014) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top